Takeshi S Komatani

Takeshi S Komatani

[email protected]

Takeshi S Komatani is currently principal of the chemical/pharma and bio/life sciences groups at Shusaku Yamamoto, and has a number of counsels including in academia, start-ups, and big pharma in Japanese and non-Japanese entities.

Takeshi received his PhD from the University of Tokyo, Japan, with Professor K Inoue, and qualified as a Japanese licensed, registered pharmacist (chemist) with a certificate of Kampo and natural medicines specialist qualification. He was a researcher at F Hoffmann-La Roche in Basle, Switzerland. Thereafter, he joined Shusaku Yamamoto, a patent and law firm in Osaka, Japan, in 1998, and was registered to practise before the Japanese Patent Office and appear as patent and trademark counsel before the Japanese courts, admitted in 2000. He was registered as an IP litigation certified attorney before the Japanese courts in 2004. He has completed the EU-recognised PharmaTrain course on implementing reliable standards for high-quality postgraduate education and training in medicines development, at Osaka University in 2017. He also received an LLB from Keio University in 2019. In 2019, he also qualified as a Board Certified Member of the Japanese Association of Pharmaceutical Medicine, which is equivalent to having completed CPI (Certified Physician Investigator)accredited by ACRP (Association of Clinical Research Professionals).

He is a member of the International Association for the Protection of Intellectual Property (AIPPI) and vice chair of TRIPS standing committee since 2018, and a member of the editorial board of the Pharmaceutical Patent Analyst (UK) since 2012. He is also a member of the Japan Patent Attorneys Association, the Asian Patent Attorneys Association, the Intellectual Property Association of Japan, the Pharmaceutical Society of Japan, the Japan Pharmaceutical Association, the American Association for the Advancement of Science and the Certified Specialist Association of Intellectual Property Management. He has lectured, and contributed a number of articles, extensively on Japanese and international/trilateral IP and pharma law/practice.

Content from this contributor


The Law Reviews content